Drugs / QCZ484
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06905327 | Mar 2023 → Sep 2024 | hypertensive disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07610278 | May 2026 → Apr 2027 expected | hyperlipidemia | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 2 | NCT07543120 | May 2026 → May 2031 expected | hypertensive disorder | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 2 | NCT06857955 | Mar 2025 → Jan 2027 expected | hypertensive disorder | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QCZ484 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07543120 ↗ |
| Route | Subcutaneous | “given subcutaneously” NCT06857955 ↗ |